Research programme: anti-cancer therapeutics - ConverGene

Drug Profile

Research programme: anti-cancer therapeutics - ConverGene

Alternative Names: CG-223; CG-250

Latest Information Update: 12 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ConverGene
  • Developer ConverGene; University of Maryland School of Medicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 05 Apr 2017 ConverGene establishes CRADA with the National Institute of Neurological Disorders and Stroke for the development of anti-caner therapeutics
  • 25 Jan 2017 ConverGene and University of Maryland agree to co-develop CG 223 and CG 250 in USA for Acute myelogenous leukemia
  • 25 Jan 2017 Preclinical trials in Acute myeloid leukaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top